Individual susceptibility varies between regional, racial, and cultural groups, and it is commonly assumed that, in addition to environmental and occupational exposures, genetic background and lifestyle (e.g. diet selection) significantly contribute to this variability. In human studies, however, it is difficult to study exposure- gene interactions because human populations contain complex substructures that are the product of social, racial, and regional differences. In addition, different lifestyles are interconnected and often create multiple beneficial or adverse habits. To model a genetically heterogeneous human population, the Collaborative Cross (CC) mice were created to represent a complete intermixed mouse population covering all possible genotypes. In the proposed work, we hypothesize that the variability in susceptibility derived solely from genetic diversity can be modeled in mice by combining the CC model with the 1, 3-butadiene (BD) exposure model. BD was chosen as a model compound because it forms several protein adducts that are biomarkers for BD uptake, metabolic activation, and detoxification. These N-terminal valine adducts will be used to assess susceptibility of the CC population. BD metabolism is dependent on P450 2e1 activity, and therefore we further hypothesize that BD-derived protein adducts correlate with P450 2e1 activity. To test these hypotheses we propose in aim 1 to demonstrate the range of carcinogen metabolism derived from genetic diversity and in aim 2 to determine whether differences in carcinogen metabolism are mediated via regulation of P450 2e1 activity. Therefore, we propose to expose CC mice to BD and determine relative potency for metabolic activation versus detoxification derived solely from genetic diversity. The Relative potency for metabolic activation (RPoMA) will be calculated from BD-derived protein adducts by applying a recently established multiplicative risk model. Because 90% of BD is metabolized by P450 2e1, its enzymatic activity in liver tissues from CC mice will be determined to specifically investigate the role of P450 2e1 in BD metabolism as it relates to susceptibility. If successful, this proposal will show the relatie contributions of genetic background on carcinogen metabolism and reveal the importance of P450 2e1 across various genetic backgrounds.
This study will investigate the variability in metabolic activation of carcinogens derived solely from genetic diversity. As a model for human genetic diversity, the unique Collaborative Cross mouse population will be treated with the model carcinogen 1, 3-butadiene (BD) and variability in BD metabolism will be determined based on protein adducts as biomarkers.
| Hartman, Jessica H; Miller, Grover P; Caro, Andres A et al. (2017) 1,3-Butadiene-induced mitochondrial dysfunction is correlated with mitochondrial CYP2E1 activity in Collaborative Cross mice. Toxicology 378:114-124 |
| Hartman, Jessica H; Miller, Grover P; Boysen, Gunnar (2014) Inhibitory potency of 4-carbon alkanes and alkenes toward CYP2E1 activity. Toxicology 318:51-8 |
| Pianalto, Kaila M; Hartman, Jessica H; Boysen, Gunnar et al. (2013) Differences in butadiene adduct formation between rats and mice not due to selective inhibition of CYP2E1 by butadiene metabolites. Toxicol Lett 223:221-7 |
| Hartman, Jessica H; Boysen, Gunnar; Miller, Grover P (2013) Cooperative effects for CYP2E1 differ between styrene and its metabolites. Xenobiotica 43:755-64 |
| Hartman, Jessica H; Boysen, Gunnar; Miller, Grover P (2012) CYP2E1 metabolism of styrene involves allostery. Drug Metab Dispos 40:1976-83 |
